Ryvu Therapeutics S.A. Annual Report 2021

Read More

Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement

Read More

Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain

Read More

Change order to the statement of work

Read More

Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases

Read More

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

Ryvu Therapeutics S.A. Q3 2021 Financial Report

Read More

Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference

Read More

Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia

Read More